about
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesSOX9-regulated cell plasticity in colorectal metastasis is attenuated by rapamycinCombination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinomaA phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.Management of multicellular senescence and oxidative stress.Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.Targeting mTOR network in colorectal cancer therapyPrognostic and Predictive Biomarkers in Colorectal Cancer: Implications for the Clinical Surgeon.
P2860
Q27015224-E620D1CD-4B79-4C21-9177-1EEC26F797CDQ28387834-C94B6D78-22A4-4763-8019-E93444FA8D61Q34977124-2AE9E72F-63ED-4A64-B38D-4994BFEE4C7CQ35896874-4EA32020-D486-4E93-BFA6-333C0441F4DEQ37191067-30EE6581-BEDC-4AB6-9F81-D4643B17D415Q37602717-85026318-3848-4FFB-95A4-675D3DA29EA4Q37708005-6BA811ED-F358-429B-9E0F-74243E206A32Q38555225-957D69BB-AC58-4C21-A54E-1524AC790787
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Everolimus in colorectal cancer.
@en
type
label
Everolimus in colorectal cancer.
@en
prefLabel
Everolimus in colorectal cancer.
@en
P2860
P1476
Everolimus in colorectal cancer.
@en
P2093
Herbert Hurwitz
Ivy Altomare
P2860
P304
P356
10.1517/14656566.2013.770473
P407
P577
2013-02-13T00:00:00Z